In­di­v­ior opens up a $30M R&D cen­ter; Lil­ly strikes dis­cov­ery deal with Topas

⇨ Eli Lil­ly $LLY has turned to Ger­many’s Topas Ther­a­peu­tics for a new dis­cov­ery deal cov­er­ing drugs for in­flam­ma­to­ry or au­toim­mune con­di­tions. As part of the deal pack­age Tops will get R&D sup­port from the phar­ma gi­ant while Lil­ly gets an op­tion on the drugs the part­ners find. Terms weren’t dis­cussed. Topas CEO Timm Jessen said: “We ex­pect this work to sup­port the val­ue of our ap­proach in in­duc­ing tol­er­ance al­so against ex­ter­nal anti­gens. Ad­di­tion­al­ly, the in­ter­est from such an im­por­tant phar­ma­ceu­ti­cal com­pa­ny in our tech­nol­o­gy, we be­lieve, sup­ports the strong com­mer­cial po­ten­tial of our work.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER